Next Article in Journal
Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles
Next Article in Special Issue
Combining Recombinase-Mediated Cassette Exchange Strategy with Quantitative Proteomic and Phosphoproteomic Analyses to Inspect Intracellular Functions of the Tumor Suppressor Galectin-4 in Colorectal Cancer Cells
Previous Article in Journal
Linking Reactive Oxygen Species (ROS) to Abiotic and Biotic Feedbacks in Plant Microbiomes: The Dose Makes the Poison
Perspective

Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions

1
Biobohemia, Inc., 1 Broadway, 14th Floor, Cambridge, MA 02142, USA
2
Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, 119121 Moscow, Russia
*
Author to whom correspondence should be addressed.
Academic Editor: Stanislav Naryzhny
Int. J. Mol. Sci. 2022, 23(8), 4401; https://doi.org/10.3390/ijms23084401
Received: 23 February 2022 / Revised: 12 April 2022 / Accepted: 12 April 2022 / Published: 15 April 2022
(This article belongs to the Special Issue Proteomics and Its Applications in Cancers)
The creation of cancer vaccines is a constant priority for research and biotechnology. Therefore, the emergence of any new technology in this field is a significant event, especially because previous technologies have not yielded results. Recently, the development of a cancer vaccine has been complemented by a new proteomics technology platform that allows the creation of antigen compositions known as antigenic essences. Antigenic essence comprises a target fraction of cellular antigens, the composition of which is precisely controlled by peptide mass spectrometry and compared to the proteomic footprint of the target cells to ensure similarity. This proteomics platform offers potential for a massive upgrade of conventional cellular cancer vaccines. Antigenic essences have the same mechanism of action, but without the disadvantages, and with notable advantages such as precise targeting of the immune response, safety, controlled composition, improved immunogenicity, addressed MHC restriction, and extended range of vaccination doses. The present paper calls attention to this novel platform, stimulates discussion of the role of antigenic essence in vaccine development, and consolidates academic science with biotech capabilities. A brief description of the platform, list of cellular cancer vaccines suitable for the upgrade, main recommendations, limitations, and legal and ethical aspects of vaccine upgrade are reported here. View Full-Text
Keywords: antigenic essence; upgrade; cancer vaccine; cell proteomic footprint; mass spectrometry; consortium antigenic essence; upgrade; cancer vaccine; cell proteomic footprint; mass spectrometry; consortium
Show Figures

Figure 1

MDPI and ACS Style

Lokhov, P.G.; Lichtenberg, S.; Balashova, E.E. Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions. Int. J. Mol. Sci. 2022, 23, 4401. https://doi.org/10.3390/ijms23084401

AMA Style

Lokhov PG, Lichtenberg S, Balashova EE. Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions. International Journal of Molecular Sciences. 2022; 23(8):4401. https://doi.org/10.3390/ijms23084401

Chicago/Turabian Style

Lokhov, Petr G., Steven Lichtenberg, and Elena E. Balashova. 2022. "Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions" International Journal of Molecular Sciences 23, no. 8: 4401. https://doi.org/10.3390/ijms23084401

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop